Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Accounts Payables (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Accounts Payables for 7 consecutive years, with $993000.0 as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables fell 26.82% year-over-year to $993000.0; the TTM value through Mar 2026 reached $993000.0, down 26.82%, while the annual FY2025 figure was $350000.0, 85.85% down from the prior year.
  • Accounts Payables hit $993000.0 in Q1 2026 for Barinthus Biotherapeutics, up from $350000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.1 million in Q3 2023 and bottomed at $350000.0 in Q4 2025.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $2.4 million recorded in 2023.
  • Year-over-year, Accounts Payables surged 113.4% in 2023 and then crashed 85.85% in 2025.
  • Barinthus Biotherapeutics' Accounts Payables stood at $3.7 million in 2022, then tumbled by 57.28% to $1.6 million in 2023, then soared by 54.53% to $2.5 million in 2024, then plummeted by 85.85% to $350000.0 in 2025, then skyrocketed by 183.71% to $993000.0 in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $993000.0, $350000.0, and $698000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.